Rabbit renal cortical microsomes metabolize arachidonic acid to trihydroxyeicosatrienoic acids

Bisallylic hydroxylation and epoxidation of polyunsaturated fatty acids by cytochrome P450

Polyunsaturated fatty acids can be oxygenated by cytochrome P450 to hydroxy and epoxy fatty acids. Two major classes of hydroxy fatty acids are formed by hydroxylation of the omega-side chain and by hydroxylation of bisallylic methylene carbons. Bisallylic cytochrome P450-hydroxylases transform linoleic acid to 11-hydroxylinoleic acid, arachidonic acid to 13-hydroxyeicosa-5Z,8Z,11Z,14Z-tetraenoic acid, 10-hydroxyeicosa-5Z,8Z,11Z,14Z-tetraenoic acid and 7-hydroxyeicosa-5Z,8Z,11Z,14Z-tetraenoic acid and eicosapentaenoic acid to 16-hydroxyeicosa-5Z,8Z,11Z,14Z,17Z-pent aenoic acid, 13-hydroxyeicosa-5Z,8Z,11Z,14Z,17Z-pent aenoic acid and 10-hydroxyeicosa-5Z,8Z,11Z,14Z,17Z-pent aenoic acid as major metabolites. The bisallylic hydroxy fatty acids are chemically unstable and decompose rapidly to cis-trans conjugated hydroxy fatty acids during acidic extractive isolation. Bisallylic hydroxylase activity appears to be augmented in microsomes induced by the synthetic glucocorticoid dexamethasone and by some other agents, but the P450 gene families of these hydroxylases have yet to be determined. The fatty acid epoxides, which are formed by cytochrome P450, are chemically stable, but are hydrolyzed to diols by soluble epoxide hydrolases. Epoxidation of polyunsaturated fatty acids is a prominent pathway of metabolism in the liver and the renal cortex and epoxy-genase activity appears to be under homeostatic control in the kidney. Many arachidonate epoxygenases have been identified belonging to the CYP2C gene subfamily. Epoxygenases have also been found in the central nervous system, endocrine organs, the heart and endothelial cells. Epoxides of arachidonic acid have been found to exert pharmacological effects on many cells.

Oxygenation of polyunsaturated fatty acids by cytochrome P450 monooxygenases

Polyunsaturated fatty acids can be oxygenated by P450 in different ways--by epoxidation, by hydroxylation of the omega-side chain, by allylic and bis-allylic hydroxylation and by hydroxylation with double bond migration. Major organs for these oxygenations are the liver and the kidney. P450 is an ubiquitous enzyme. It is therefore not surprising that some of these reactions have been found in other organs and tissues. Many observations indicate that P450 oxygenates arachidonic acid in vivo in man and in experimental animals. This is hardly surprising. omega-Oxidation was discovered in vivo 60 years ago. It was more unexpected that biological activities have been associated with many of the P450 metabolites of arachidonic acid, at least in pharmacological doses. Epoxygenase metabolites of arachidonic acid have attracted the largest interest. In their critical review on epoxygenase metabolism of arachidonic acid in 1989, Fitzpatrick and Murphy pointed out some major differences between the PGH synthase, the lipoxygenase and the P450 pathways of arachidonic acid metabolism. Their main points are still valid and have only to be modified slightly in the light of recent results. First, lipoxygenases show a marked regiospecificity and stereospecificity, while many P450 seem to lack this specificity. There are, however, P450 isozymes which catalyse stereospecific epoxidations or hydroxylations. Many hydroxylases and at least some epoxygenases also show regiospecificity, i.e. oxygenate only one double bond or one specific carbon of the fatty acid substrate. In addition, preference for arachidonic acid and eicosapentaenoic acid may occur in the sense that other fatty acids are oxygenated with less regiospecificity. A more important difference is that prostaglandins and leukotrienes affect specific and well characterised receptors in cell membranes, while receptors for epoxides of arachidonic acid or other P450 metabolites have not been characterised. Nevertheless, epoxides of arachidonic acid have been found to induce a large number of different pharmacological effects. In some systems, effects have been noted at pm concentrations which might conceivably be in the physiological concentration range of these epoxides, e.g. after release from phospholipids by phospholipase A2. An intriguing possibility is that the effects of [Ca]i on different ion channels might possibly explain their biological actions. In situations when pharmacological doses are used, metabolism to epoxyprostanoids or other interactions with PGH synthase could also be of importance. Finally, one report on a specific receptor for 14R,15S-EpETrE in mononuclear cell membranes has just been published.(ABSTRACT TRUNCATED AT 400 WORDS)

Activation of osmolyte efflux from cultured renal papillary epithelial cells

The rabbit renal papillary epithelial cell line PAP-HT25 accumulates sorbitol and other organic osmolytes when cultured in hypertonic media. When returned to isotonic media, PAP-HT25 cells swell because of water influx and then shrink to their normal volume because of rapid osmolyte and water efflux (volume regulatory decrease, VRD). Sorbitol efflux from PAP-HT25 cells during VRD was reduced to 18% of control by incubation of the cells with 100 microM eicosatetraynoic acid (ETYA), indicating that an enzyme that metabolizes arachidonic acid (AA) is a key component of the efflux process. Sorbitol efflux was unaffected by incubation with cyclooxygenase and lipoxygenase inhibitors but was reduced to 9% by incubation with 100 microM ketoconazole and to 37% by incubation with 100 microM SKF-525A, indicating that the cytochrome P-450 limb of the AA cascade is involved in the efflux process. The efflux of other organic osmolytes betaine and myoinositol, but not glycerolphosphorylcholine, was also inhibited by incubation with ETYA and ketoconazole.

Some properties of gingival 12-lipoxygenase activity in human and dog

Arachidonate lipoxygenase activity in gingival tissue was investigated and compared with that of enzymes from other sources. 12-lipoxygenase activity was detected in homogenates of human and dog gingiva after 2 min incubation with exogenous arachidonic acid. 12-HETE was the major metabolite in both species. The 12-lipoxygenase activity in homogenates of human gingiva and in platelets was inhibited by EDTA; it recovered after the addition of a divalent cation such as Ca2+. Its activity in dog gingiva and platelets was not affected by the chelator. Gingival 12-lipoxygenase, unlike platelet 12-lipoxygenase, was inhibited by AA861, a possible 5-lipoxygenase inhibitor. These findings suggest that gingival tissue has high levels of 12-lipoxygenase activity, but the enzyme in human gingiva differs from that in the dog in its dependency upon divalent cations, and gingival 12-lipoxygenase differs from the same enzyme in platelets in its sensitivity to an inhibitor.

Cytochrome P450-dependent arachidonic acid metabolism in human kidney

Cytochrome P450-dependent arachidonic acid metabolism in human kidney cortex from several postmortem subjects has been characterized. Using HPLC and GC/MS, four cytochrome P450-arachidonic acid metabolites were tentatively but not unequivocally identified as epoxyeicosatrienoic acid (EET), dihydroxyeicosatrienoic acid (DHT) and 19- and 20-hydroxyeicosatetraenoic acids, suggesting the involvement of two major cytochrome P450 enzymes, epoxygenase and omega/omega-1 hydroxylases. This pattern of metabolism was similar to that found in rabbit and rat kidneys. The formation of these metabolites was dependent on the presence of NADPH and inhibited by IgG of NADPH-cytochrome P450 (c) reductase. Immunologic studies of renal cytochrome P450 epoxygenase demonstrated that antibodies prepared against human-purified hepatic cytochrome P450 epoxygenase recognized renal enzyme protein and inhibited the enzyme activity by 92%. In contrast, control immunoglobulin did not inhibit renal cytochrome P450 epoxygenase. Antibody inhibition of renal cytochrome P450 epoxygenase demonstrated a degree of conservation of both enzyme proteins between liver and kidney. Antibodies against lauric acid omega/omega-1 hydroxylases (P450 omega) inhibited the formation of omega/omega-1 hydroxylase products, 19- and 20-HETEs. Identical qualitative patterns of arachidonic acid metabolites were observed in all cortical microsomes studied. Interindividual variations were observed in the cytochrome P450-dependent arachidonic acid metabolism, and the activities ranged from 0.031 to 5.027 nmol arachidonic acid converted/mg protein/30 min. which is about a 150-fold difference. However, when the specific activities for total cytochrome P450-dependent arachidonic acid metabolism were calculated, two separate groups could be distinguished, high and low metabolizers of arachidonic acid.(ABSTRACT TRUNCATED AT 250 WORDS)

Deactivation of sulindac-sulphide by human renal microsomes

The renal metabolism of sulindac-sulphide was studied in subcellular fractions from human kidney. It was shown that renal microsomes, in the presence of NADPH, effectively catalyzed the sulphoxidation of sulindac-sulphide. Also the mitochondrial fraction catalyzed the reaction but at a ten-fold lower rate than the microsomes. Carbon monoxide, metyrapone and n-octylamine did not inhibit renal sulphoxidation of sulindac-sulphide and the reaction could occur in a monooxygenase containing fraction free from NADPH-cytochrome P-450 reductase. Hydroxylation of lauric acid was studied in microsomes and in the purified monooxygenase containing fraction under the same experimental condition as sulindac-sulphide sulphoxidation. Lauric acid is a substrate known to be metabolized by a renal cytochrome P-450 to 11 and 12-hydroxylated products. This reaction was sensitive to carbon monoxide and did not occur in the absence of NADPH cytochrome P-450 reductase. Based on these results we conclude that cytochrome P-450 plays at the most a limited role in human kidney metabolism of sulindac-sulphide. In contrast, sulphoxidation of sulindac-sulphide was substantially reduced in the presence of methimazole suggesting a role of the flavin-containing monooxygenase in the renal biotransformation of sulindac-sulphide in man.

Novel renal arachidonate metabolites

Cells of the thick ascending limb of the loop of Henle (TALH) metabolize arachidonic acid (AA) via the cytochrome P450 monooxygenase system to biologically active products that are resolved into two peaks, P1 and P2, on reverse-phase HPLC. Each peak contains materials that have characteristic biological activity. P1 contains a material that relaxes blood vessels and is structurally similar to a vasodilator, the 5,6 epoxyeicosatrienoic acid (EET). P2 contains a material that inhibits cardiac Na+-K+-ATPase, the major component of which has been identified as the 11,12 dihydroxyeicosatrienoic acid. In mTALH cells obtained from rabbits made hypertensive by aortic coarctation, there was a selective increase in P1 and P2 formation compared to other renomedullary cells. We have identified AA metabolites in bovine corneal epithelium with biological properties and chemical features similar to those of mTALH cells. 12(R)hydroxyeicosatetraenoic acid (12(R) HETE) a possible derivative of the 11,12-EET, is produced by the cornea and also has been shown to inhibit Na+-K+-ATPase activity. Renal microsomes obtained from spontaneously hypertensive rats (SHRs) also metabolize AA via a cytochrome P450 monooxygenase pathway to three principal biologically active metabolites that are formed in increased amounts during the developmental phase of hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)

Renal cytochrome P-450-dependent metabolism of arachidonic acid in spontaneously hypertensive rats

Renal cytochrome P-450-dependent monooxygenases metabolize arachidonic acid to products some of which affect vascular tone and (Na+,K+)ATPase activity. We measured these metabolites in spontaneously hypertensive (SHR) and control normotensive Wister-Kyoto (WKY) rats. Systolic tail blood pressure in SHR increased from 112 to 202 mm Hg and in WKY from 97 to 136 mm Hg at 5 and 20 weeks respectively. Renal cortical and outer medullary microsomes were incubated with [14C]arachidonic acid; metabolites formed via the cytochrome P-450 pathway were defined as those dependent on NADPH, inhibited by SKF-525A, and unaffected by indomethacin. The P-450-dependent metabolites were higher in SHR vs WKY at 5, 7 and 11 weeks in the cortex and at 7 and 11 weeks in the outer medulla. In the outer medulla, the formation of these metabolites peaked at 7 weeks. Using reverse-phase HPLC, the cytochrome P-450-dependent metabolites were separated into three radioactive peaks: peak I had a retention time of 17.5 min and comigrated as 11,12-dihydroxyeicosatrienoic acid standard. Peak II had a retention time of 19 min and comigrated with omega-hydroxylation compounds. Peak III had a retention time of 27 min and comigrated with 11,12-epoxyeicosatrienoic acid. In the renal cortex, peak I was higher in SHR vs WKY at 5, 7, and 9 weeks and peak III at 5, 7, 9 and 11 weeks. In the outer medulla, peak I was higher in SHR at 5 and 7 weeks, and peaks II and III at 7 weeks. Cytochrome P-450 content in the renal cortex was always higher in SHR vs WKY. We conclude that renal cytochrome P-450-dependent metabolites of arachidonic acid may participate in the circulatory changes of SHR, particularly during the developmental stage.

12(R)-hydroxyicosatetraenoic acid: a cytochrome-P450-dependent arachidonate metabolite that inhibits Na+,K+-ATPase in the cornea

When corneal microsomes were incubated with arachidonic acid in the presence of an NADPH-generating system, four polar metabolites (compounds A-D) were formed. Synthesis of these metabolites could be inhibited by carbon monoxide, SKF 525A, and anti-cytochrome c reductase antibodies. One of the metabolites, compound C, was found to inhibit partially purified Na+,K+-ATPase from the corneal epithelium in a dose-dependent manner with an ID50 of approximately 50 nM. After compound C was purified by TLC and HPLC, it was found to have a UV absorption spectrum with a maximum absorbance at 236 nm suggesting the presence of a conjugated diene. Mass spectrometric analysis using positive- and negative-ionization modes was carried out on derivatized compound C that had been synthesized from a mixture of specifically labeled ([5,6,8,9,11,12,14,15-2H8]arachidonic acid) and unlabeled arachidonic acid. Abundant fragment ions were consistent with compound C being a monooxygenated derivative of arachidonic acid with a hydroxyl substituent at carbon-12 of the icosanoid backbone; all deuterium atoms from [2H8]arachidonate were retained in the structure. Oxidative ozonolysis yielded products indicating double bonds between carbons at positions 10 and 11 and positions 14 and 15 of the 20-carbon chain. Compound C was, therefore, characterized as a 12-hydroxyicosatetraenoic acid. However, only 12(R) isomer was found to be an inhibitor of the Na+,K+-ATPase from the corneal epithelium, suggesting that the biologically active compound C was 12(R)-hydroxy-5,8,10,14-icosatetraenoic acid. Such an inhibitor of Na+,K+-ATPase synthesized in the cornea may have an important role in regulating ocular transparency and aqueous human secretion.

Immunochemical studies on the contribution of NADPH cytochrome P-450 reductase to the cytochrome P-450-dependent metabolism of arachidonic acid

We have studied the role of NADPH cytochrome P-450 reductase in the metabolism of arachidonic acid and in two other monooxygenase systems: aryl hydrocarbon hydroxylase and 7-ethoxyresorufin-o-deethylase. Human liver NADPH cytochrome P-450 reductase was purified to homogeneity as evidenced by its migration as a single band on SDS gel electrophoresis, having a molecular weight of 71,000 Da. Rabbits were immunized with the purified enzyme and the resulting antibodies were used to evaluate the involvement of the reductase in cytochrome P-450-dependent arachidonic acid metabolism by bovine corneal epithelial and rabbit renal cortical microsomes. A highly sensitive immunoblotting method was used to identify the presence of NADPH cytochrome P-450 reductase in both tissues. We used these antibodies to demonstrate for the first time the presence of cytochrome c reductase in the cornea. Anti-NADPH cytochrome P-450 reductase IgG, but not anti-heme oxygenase IgG, inhibited the NADPH-dependent arachidonic acid metabolism in both renal and corneal microsomes. The inhibition was dependent on the ratio of IgG to microsomal protein where 50% inhibition of arachidonic acid conversion by cortical microsomes was achieved with a ratio of 1:1. A higher concentration of IgG was needed to achieve the same degree of inhibition in the corneal microsomes. The antibody also inhibited rabbit renal cortical 7-ethoxyresorufin-o-deethylase activity, a cytochrome P-450-dependent enzyme. However, the anti-NADPH cytochrome P-450 reductase IgG was much less effective in inhibiting rabbit cortical aryl hydrocarbon hydroxylase. Thus, the degree of inhibition of monooxygenases by anti-NADPH cytochrome P-450 reductase IgG is variable. However, with respect to arachidonic acid, NADPH cytochrome P-450 reductase appears to be an integral component for the electron transfer to cytochrome P-450 in the oxidation of arachidonic acid.

Regulation of arachidonic acid metabolism by cytochrome P-450 in rabbit kidney

Renal microsomal cytochrome P-450-dependent arachidonic acid metabolism was correlated with the level of cytochrome P-450 in the rabbit kidney. Cobalt, an inducer of haem oxygenase, reduced cytochrome P-450 in both the cortex and medulla in association with a 2-fold decrease in aryl-hydrocarbon hydroxylase, an index of cytochrome P-450 activity, and a similar decrease in the formation of cytochrome P-450-dependent arachidonic acid metabolites by renal microsomes (microsomal fractions). Formation of the latter was absolutely dependent on NADPH addition and was prevented by SKF-525A, an inhibitor of cytochrome P-450-dependent enzymes. Arachidonate metabolites of cortical microsomes were identified by g.c.-m.s. as 20- and 19-hydroxyeicosatetraenoic acid, 11,12-epoxyeicosatrienoic acid and 11,12-dihydroxyeicosatrienoic acid. The profile of arachidonic acid metabolites was the same for the medullary microsomes. Induction of cytochrome P-450 by 3-methylcholanthrene and beta-naphthoflavone increased cytochrome P-450 content and aryl-hydrocarbon hydroxylase activity by 2-fold in the cortex and medulla, and this correlated with a 2-fold increase in arachidonic acid metabolites via the cytochrome P-450 pathway. These changes can also be demonstrated in cells isolated from the medullary segment of the thick ascending limb of the loop of Henle, which previously have been shown to metabolize arachidonic acid specifically via the cytochrome P-450-dependent pathway. The specific activity for the formation of arachidonic acid metabolites by this pathway is higher in the kidney than in the liver, the highest activity being in the outer medulla, namely 7.9 microgram as against 2.5 micrograms of arachidonic acid transformed/30 min per nmol of cytochrome P-450 for microsomes obtained from outer medulla and liver respectively. These findings are consistent with high levels of cytochrome P-450 isoenzyme(s), specific for arachidonic acid metabolism, primarily localized in the outer medulla.

Biochemistry and pharmacology of renal arachidonic acid metabolism

Arachidonic acid is metabolized to prostaglandin, lipoxygenase products, and products of the microsomal cytochrome P-450 enzymes of the kidney. The distribution of the metabolizing enzymes and their regulation and pharmacologic manipulation are reviewed. The mechanisms of release of arachidonic acid from membrane lipids through a surface-mediated receptor mechanism are also discussed. The localization of the various enzymes and product formation may have profound effects on glomerular filtration, renal blood flow, and electrolyte excretion. Therefore, an understanding of the potential sites of inhibition of the nonsteroidal anti-inflammatory drugs is important in assessing their effects on renal function.

Prostaglandins and other arachidonic acid metabolites in the kidney

This very brief summary of the various possible contributions of PG to normal and abnormal renal function should highlight the problem of assigning a specific role to PG in overall renal physiology and pathophysiology. PG produced in specific segments of the nephron will affect specific functions occurring in this segment. These effects need not necessarily be reflected in the overall renal function. Also in some cases, the determinant may not be prostaglandins, that is, cyclooxygenase derivatives of AA, but perhaps lipoxygenase or epoxygenase products that influence the functional parameters of the specific segment. Despite the multitude of renal functions that may be influenced by PG, we would like to propose a teleological hypothesis for an overall role of PG in the kidney, that is, that of cytoprotective agents. Renal vasodilatatory prostaglandins will maintain renal blood flow when the latter is challenged, thus, preventing hypoxic injury to the tissue. Endogenous prostaglandins may also protect tubular cells from extreme environmental changes as may occur on both the luminal and contraluminal sides. For example, tubular cells may be exposed to luminal fluid that may vary from hypotonic to hypertonic, from alkaline to acid, and so forth. Similarly, the interstitial fluid osmolality and solute composition is subject to considerable variations which may be opposite to those existing on the urinary side. The role of PG might be to maintain the internal milieu of the cells exposed to such extreme changes in environment. This could be accomplished by changing the permeability characteristics of the membranes and the function of pumps. Thus, specific PGs could dampen the hormonal response to protect the specific nephron segment, which might otherwise suffer injury. This hypothesis might also help to explain why the effect of PG administration or inhibition of PG synthesis may vary considerably depending on the overall physiological state of the subject: Maintenance of a local internal milieu may require different responses from those required for total body homeostasis.

Cytochrome P450 dependent metabolism of arachidonic acid in bovine corneal epithelium

Microsomes prepared from bovine corneal epithelium metabolized 14C-arachidonic acid into two unidentified products, separated by thin-layer chromatography and called Peaks I and II. Each peak was further separated by high performance liquid chromatography into two metabolites. The formation of these metabolites was dependent on the addition of NADPH and inhibited by carbon monoxide and SKF-525A, suggesting a cytochrome P450-dependent mechanism. The presence of cytochrome P450 in the corneal epithelium was assessed directly by measurement of the carbon monoxide reduced spectrum and indirectly by measuring aryl hydrocarbon hydroxylase activity. The activity of aryl hydrocarbon hydroxylase was protein- and NADPH-dependent and was inhibited by SKF-525A.

Partial purification and characterization of arachidonate 12-lipoxygenase from rat lung

Incubation of rat lung cytosol with arachidonic acid produced 12-hydroxy-5,8,10,14-eicosatetraenoic acid as a major product, which was identified by gas chromatography-mass spectrometry. By ammonium sulfate fractionation and DEAE-cellulose chromatography the arachidonate 12-lipoxygenase was purified about 30-fold from the rat lung cytosol. The partially purified enzyme was mostly free of the glutathione peroxidase activity and transformed arachidonic acid to its 12-hydroperoxide. 5,8,11,14,17-Eicosapentaenoic acid was also an active substrate, and the oxygenation at C-12 was confirmed by mass spectrometry. A significant amount of 12-lipoxygenase activity was also found in the microsomes and other particulate fractions.

Metabolism of arachidonic acid by isolated rat hepatocytes, renal cells and by some rabbit tissues. Detection of vicinal diols by mass fragmentography

Purified cytochromes P-450 (LM2 and PB-B2) in a reconstituted system and epoxide hydrolase were recently found to metabolize arachidonic (eicosatetraenoic) acid to four vicinal dihydroxyeicosatrienoic acids. These metabolites were chemically synthetized from octadeuterated arachidonic acid and employed as internal standards for mass fragmentography. Isolated rat hepatocytes and renal cells were incubated with arachidonic acid (0.1 mM; 37 degrees C, 15 min) and, following extractive isolation and reversed-phase HPLC, formation of 11,12-dihydroxy-5,8,14-eicosatrienoic acid and 14,15-dihydroxy-5,8,11-eicosatrienoic acid was demonstrated by mass fragmentography using a capillary GC column. Furthermore, these diols were also detected in rabbit liver and renal cortex and they therefore appear to be formed endogenously. Formation of vicinal diols was also studied in cell free systems. Rabbit liver and renal cortical microsomes were incubated with NADPH (1 mM) and arachidonic acid (0.15 mM) for 15 min at 37 degree C and, besides 11,12-dihydroxy- and 14,15-dihydroxyeicosatrienoic acid, small amounts of 8,9-dihydroxy- and 5,6-dihydroxyeicosatrienoic acid could be detected by mass fragmentography. Renal as wall as hepatic monooxygenases can thus epoxidize each of the four double bonds of arachidonic acid. In contrast, rabbit lung microsomes and NADPH metabolized arachidonic acid mainly to prostaglandins and 19-hydroxy- and 20-hydroxyarachidonic acid, while only small amounts of 11,12-dihydroxyeicosatrienoic acid could be found. Monooxygenase metabolism of arachidonic acid by epoxidation might therefore be a significant pathway for the metabolism of this essential fatty acid in isolated rat renal cells and hepatocytes but presumably not in the lung.